These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 19708826)

  • 1. QSAR of cytochrome inhibitors.
    Roy K; Roy PP
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1245-66. PubMed ID: 19708826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.
    Crivori P; Poggesi I
    Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative structure-activity relationships (QSARs) within series of inhibitors for mammalian cytochromes P450 (CYPs).
    Lewis DF; Dickins M
    J Enzyme Inhib; 2001 Oct; 16(4):321-30. PubMed ID: 11916137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
    Kontijevskis A; Komorowski J; Wikberg JE
    J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of drug-like molecular properties: modeling cytochrome p450 interactions.
    Jalaie M; Arimoto R; Gifford E; Schefzick S; Waller CL
    Methods Mol Biol; 2004; 275():449-520. PubMed ID: 15141126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.
    Ekins S; de Groot MJ; Jones JP
    Drug Metab Dispos; 2001 Jul; 29(7):936-44. PubMed ID: 11408357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.
    Appiah-Opong R; de Esch I; Commandeur JN; Andarini M; Vermeulen NP
    Eur J Med Chem; 2008 Aug; 43(8):1621-31. PubMed ID: 18249473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochromes P450 and drug discovery.
    Lamb DC; Waterman MR; Kelly SL; Guengerich FP
    Curr Opin Biotechnol; 2007 Dec; 18(6):504-12. PubMed ID: 18006294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition and induction of human cytochrome P450 enzymes: current status.
    Pelkonen O; Turpeinen M; Hakkola J; Honkakoski P; Hukkanen J; Raunio H
    Arch Toxicol; 2008 Oct; 82(10):667-715. PubMed ID: 18618097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classification of cytochrome P450 inhibitors with respect to binding free energy and pIC50 using common molecular descriptors.
    Dagliyan O; Kavakli IH; Turkay M
    J Chem Inf Model; 2009 Oct; 49(10):2403-11. PubMed ID: 19777996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding CYP2D6 interactions.
    de Groot MJ; Wakenhut F; Whitlock G; Hyland R
    Drug Discov Today; 2009 Oct; 14(19-20):964-72. PubMed ID: 19638317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.
    Masubuchi Y; Horie T
    Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: from the laboratory to the clinic.
    Rendić S
    Croat Med J; 1999 Sep; 40(3):357-67. PubMed ID: 10411963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450s in the development of target-based anticancer drugs.
    Purnapatre K; Khattar SK; Saini KS
    Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
    Foti RS; Wahlstrom JL
    IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.
    Venkatakrishnan K; Obach RS; Rostami-Hodjegan A
    Xenobiotica; 2007; 37(10-11):1225-56. PubMed ID: 17968744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.
    Hollenberg PF; Kent UM; Bumpus NN
    Chem Res Toxicol; 2008 Jan; 21(1):189-205. PubMed ID: 18052110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.
    Korolev D; Balakin KV; Nikolsky Y; Kirillov E; Ivanenkov YA; Savchuk NP; Ivashchenko AA; Nikolskaya T
    J Med Chem; 2003 Aug; 46(17):3631-43. PubMed ID: 12904067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
    Peng CC; Rushmore T; Crouch GJ; Jones JP
    Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods.
    Hudelson MG; Ketkar NS; Holder LB; Carlson TJ; Peng CC; Waldher BJ; Jones JP
    J Med Chem; 2008 Feb; 51(3):648-54. PubMed ID: 18211009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.